Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Biliary Tract Diseases

Free Subscription Articles published in J Gastroenterol Retrieve available abstracts of 41 articles: HTML format

Single Articles

August 2026
1. WIESSNER JR, Kis M, Lenggenhager D, Reiner CS, et al
   Clinical course, prognostic markers, and transplant implications in COVID-19-associated secondary sclerosing cholangitis.
   J Gastroenterol. 2026 Aug 19. doi: 10.1007/s00535-026-02491.
   PubMed     Abstract available
   
   
   
2. TAKEDA T, Sasaki T, Hirai T, Sato Y, et al
   Association of subcutaneous adiposity with survival outcomes in advanced biliary tract cancer treated with gemcitabine, cisplatin, and immune checkpoint inhibitor.
   J Gastroenterol. 2026 Aug 14. doi: 10.1007/s00535-026-02498.
   PubMed     Abstract available
   
   
   
3. HITOMI Y, Aiba Y, Ueno K, Takahashi H, et al
   rs57494551 increases CXCR5 expression and IgM(+) CXCR5(+) B-cell infiltration in the portal area of primary biliary cholangitis.
   J Gastroenterol. 2026 Aug 10. doi: 10.1007/s00535-026-02493.
   PubMed     Abstract available
   
   
   June 2026
4. MIZUNO K, Chretien B, Nishida K, Ito T, et al
   Vonoprazan is associated with a phenotype-specific increase in cholangitis reporting in immune checkpoint inhibitor-treated patients: a VigiBase pharmacovigilance study.
   J Gastroenterol. 2026 Jun 26. doi: 10.1007/s00535-026-02469.
   PubMed     Abstract available
   
   
   
5. SOUSA JM, Rodriguez-Tajes S, Hernandez-Guerra M, Casado M, et al
   Prevalence and incidence of chronic kidney disease in patients with primary biliary cholangitis.
   J Gastroenterol. 2026 Jun 22. doi: 10.1007/s00535-026-02442.
   PubMed     Abstract available
   
   
   
6. SUTO H, Kumamoto K, Nagao M, Furuichi Y, et al
   Paired tumor-normal metabolomic profiling reveals alterations in choline phospholipid precursor metabolism in biliary tract cancer.
   J Gastroenterol. 2026 Jun 22. doi: 10.1007/s00535-026-02471.
   PubMed     Abstract available
   
   
   
7. MOL B, van Munster K, Weersma R, Inderson A, et al
   The longstanding issue of the benefit of ursodeoxycholic acid in primary sclerosing cholangitis: a long-term population-based study.
   J Gastroenterol. 2026 Jun 15. doi: 10.1007/s00535-026-02449.
   PubMed     Abstract available
   
   
   
8. OZMERT EH, Yee SK, Ilyas SI, Smoot RL, et al
   Emerging omics diagnosis of perihilar cholangiocarcinoma.
   J Gastroenterol. 2026 Jun 12. doi: 10.1007/s00535-026-02453.
   PubMed     Abstract available
   
   
   May 2026
9. SHIBUKI T, Hoyek C, Ramaker R, Gottam M, et al
   Clinico-molecular characteristics and enhanced efficacy of immune checkpoint inhibitors in TP53-mutated advanced biliary tract cancer.
   J Gastroenterol. 2026 May 25. doi: 10.1007/s00535-026-02439.
   PubMed     Abstract available
   
   
   April 2026
10. KO SW, Oh D, Song TJ
    Evolution of gallbladder drainage: a comprehensive review from percutaneous to endoscopic ultrasound-guided approaches.
    J Gastroenterol. 2026 Apr 24. doi: 10.1007/s00535-026-02417.
    PubMed     Abstract available
    
    
    
11. KOSAKA H, Sugimoto R, Kinoshita M, Yasuda S, et al
    Impact of TOPAZ-1 eligibility on the survival benefit of durvalumab plus gemcitabine-cisplatin in advanced biliary tract cancer: a multicenter real-world study.
    J Gastroenterol. 2026 Apr 12. doi: 10.1007/s00535-026-02412.
    PubMed     Abstract available
    
    
    
12. OKA Y, Sakai A, Masuda A, Sofue K, et al
    Prospective pilot study of functional assessment of the Sphincter of Oddi via cine-dynamic MRCP with selective inversion recovery pulse.
    J Gastroenterol. 2026;61:487-495.
    PubMed     Abstract available
    
    
    March 2026
13. OKADA H, Sugimoto S, Kayashima A, Mikami Y, et al
    Distinct phenotype of primary sclerosing cholangitis-associated inflammatory bowel disease.
    J Gastroenterol. 2026 Mar 19. doi: 10.1007/s00535-026-02388.
    PubMed     Abstract available
    
    
    February 2026
14. NAITOH I, Nakazawa T, Notohara K, Inoue D, et al
    Clinicopathological features of localized-type IgG4-related cholecystitis: a nationwide multicenter study in Japan.
    J Gastroenterol. 2026 Feb 25. doi: 10.1007/s00535-026-02353.
    PubMed     Abstract available
    
    
    January 2026
15. SHEN L, Lv T, Li S, Chen S, et al
    Factors associated with recompensation and criteria for etiological suppression in patients with primary biliary cholangitis.
    J Gastroenterol. 2026 Jan 13. doi: 10.1007/s00535-025-02342.
    PubMed     Abstract available
    
    
    November 2025
16. ZHU M, Douchi D, Murakami K, Itoh T, et al
    Correction: Molecular insights into HER2/ERBB2 amplification and carcinogenesis in gallbladder cancer associated with pancreaticobiliary maljunction.
    J Gastroenterol. 2025 Nov 26. doi: 10.1007/s00535-025-02329.
    PubMed    
    
    
    
17. INADA H, Kurano S, Miyamoto H, Onishi M, et al
    TP53 mutation predicts resistance to immune checkpoint inhibitor-based therapy in intrahepatic cholangiocarcinoma.
    J Gastroenterol. 2025 Nov 17. doi: 10.1007/s00535-025-02320.
    PubMed     Abstract available
    
    
    October 2025
18. NAKADAI Y, Ojiro K, Kasuga R, Chu PS, et al
    Validation of novel scoring systems for acute decompensated cirrhosis identifies PBC as an independent poor prognostic factor: a single-center Japanese cohort study.
    J Gastroenterol. 2025 Oct 12. doi: 10.1007/s00535-025-02310.
    PubMed     Abstract available
    
    
    
19. ZHU M, Douchi D, Murakami K, Itoh T, et al
    Molecular insights into HER2/ERBB2 amplification and carcinogenesis in gallbladder cancer associated with pancreaticobiliary maljunction.
    J Gastroenterol. 2025 Oct 4. doi: 10.1007/s00535-025-02303.
    PubMed     Abstract available
    
    
    September 2025
20. KOBAYASHI S, Nakachi K, Yamamoto K, Ueno M, et al
    Combination chemotherapy for older patients with unresectable biliary tract cancer: a prospective observational study using propensity-score matched analysis (JON2104-B).
    J Gastroenterol. 2025 Sep 6. doi: 10.1007/s00535-025-02294.
    PubMed     Abstract available
    
    
    June 2025
21. NAITOH I, Isayama H, Akamatsu N, Mizuno S, et al
    The 2024 diagnostic criteria for primary sclerosing cholangitis.
    J Gastroenterol. 2025 Jun 12. doi: 10.1007/s00535-025-02265.
    PubMed     Abstract available
    
    
    May 2025
22. ZHU J, Chen H, Meng L, Jiang J, et al
    Serum FGF19 combined with GGT and other biomarkers predicted native liver survival following Kasai portoenterostomy in early biliary atresia.
    J Gastroenterol. 2025 May 5. doi: 10.1007/s00535-025-02234.
    PubMed     Abstract available
    
    
    April 2025
23. YOSHIDA M, Toyohara T, Hori Y, Kato A, et al
    Endoscopic liquid biopsy of bile: superior diagnostic and prognostic performance of bile-derived exosomal miR-21-5p for biliary tract cancers.
    J Gastroenterol. 2025 Apr 23. doi: 10.1007/s00535-025-02250.
    PubMed     Abstract available
    
    
    February 2025
24. HAO Z, Lu Y, Hao Y, Luo Y, et al
    Correction: Fungal mycobiome dysbiosis in choledocholithiasis concurrent with cholangitis.
    J Gastroenterol. 2025 Feb 27. doi: 10.1007/s00535-025-02217.
    PubMed    
    
    
    
25. TANAKA A, Notohara K, Tobari M, Abe M, et al
    A clinicopathological study of IgG4-related autoimmune hepatitis and IgG4-hepatopathy.
    J Gastroenterol. 2025 Feb 8. doi: 10.1007/s00535-025-02221.
    PubMed     Abstract available
    
    
    November 2024
26. HAO Z, Lu Y, Hao Y, Luo Y, et al
    Fungal mycobiome dysbiosis in choledocholithiasis concurrent with cholangitis.
    J Gastroenterol. 2024 Nov 27. doi: 10.1007/s00535-024-02183.
    PubMed     Abstract available
    
    
    
27. YASUDA M, Shiokawa M, Kuwada T, Nishikawa Y, et al
    Anti-integrin alphavbeta6 autoantibody in primary sclerosing cholangitis: a Japanese nationwide study.
    J Gastroenterol. 2024 Nov 16. doi: 10.1007/s00535-024-02169.
    PubMed     Abstract available
    
    
    
28. CAO Z, Yang Y, Liu S, Sun L, et al
    FGFR2 fusions assessed by NGS, FISH, and immunohistochemistry in intrahepatic cholangiocarcinoma.
    J Gastroenterol. 2024 Nov 13. doi: 10.1007/s00535-024-02175.
    PubMed     Abstract available
    
    
    August 2024
29. TAKAOKA S, Hamada T, Nakai Y, Yasunaga H, et al
    Response to the letter by Buldukoglu et al. regarding our manuscript "Body mass index and survival among patients with advanced biliary tract cancer: a single-institutional study with nationwide data-based validation".
    J Gastroenterol. 2024 Aug 6. doi: 10.1007/s00535-024-02143.
    PubMed    
    
    
    July 2024
30. AMPUERO J, Aller R, Gallego-Duran R, Crespo J, et al
    The biochemical pattern defines MASLD phenotypes linked to distinct histology and prognosis.
    J Gastroenterol. 2024;59:586-597.
    PubMed     Abstract available
    
    
    June 2024
31. TAKAOKA S, Hamada T, Takahara N, Fukuda R, et al
    Body mass index and survival among patients with advanced biliary tract cancer: a single-institutional study with nationwide data-based validation.
    J Gastroenterol. 2024 Jun 19. doi: 10.1007/s00535-024-02124.
    PubMed     Abstract available
    
    
    May 2024
32. KANO Y, Ishikawa T, Yamao K, Mizutani Y, et al
    What is the appropriate method of pathological specimen collection for cholangiocarcinoma detection in primary sclerosing cholangitis?
    J Gastroenterol. 2024 May 7. doi: 10.1007/s00535-024-02105.
    PubMed     Abstract available
    
    
    March 2024
33. XIN HY, Zou JX, Sun RQ, Hu ZQ, et al
    Characterization of tumor microbiome and associations with prognosis in intrahepatic cholangiocarcinoma.
    J Gastroenterol. 2024 Mar 10. doi: 10.1007/s00535-024-02090.
    PubMed     Abstract available
    
    
    October 2023
34. WU JF, Peng SS, Tai CS, Lin WH, et al
    The magnetic resonance imaging and age-adjusted matrix metalloproteinase-7 assist the diagnosis of biliary atresia.
    J Gastroenterol. 2023 Oct 30. doi: 10.1007/s00535-023-02051.
    PubMed     Abstract available
    
    
    
35. WANG H, Li Y, Pu X, Liang X, et al
    MGAT5/TMEM163 variant is associated with prognosis in ursodeoxycholic acid-treated patients with primary biliary cholangitis.
    J Gastroenterol. 2023 Oct 16. doi: 10.1007/s00535-023-02045.
    PubMed     Abstract available
    
    
    September 2023
36. OZONO Y, Kawakami H, Uchiyama N, Hatada H, et al
    Current status and issues in genomic analysis using EUS-FNA/FNB specimens in hepatobiliary-pancreatic cancers.
    J Gastroenterol. 2023 Sep 12. doi: 10.1007/s00535-023-02037.
    PubMed     Abstract available
    
    
    July 2023
37. FUJITA N, Yasuda I, Endo I, Isayama H, et al
    Evidence-based clinical practice guidelines for cholelithiasis 2021.
    J Gastroenterol. 2023 Jul 15. doi: 10.1007/s00535-023-02014.
    PubMed     Abstract available
    
    
    
38. PENG M, Li H, Cao H, Huang Y, et al
    Dual FGFR and VEGFR inhibition synergistically restrain hexokinase 2-dependent lymphangiogenesis and immune escape in intrahepatic cholangiocarcinoma.
    J Gastroenterol. 2023 Jul 11. doi: 10.1007/s00535-023-02012.
    PubMed     Abstract available
    
    
    June 2023
39. XU H, Lin X, Li Z, He X, et al
    VIRMA facilitates intrahepatic cholangiocarcinoma progression through epigenetic augmentation of TMED2 and PARD3B mRNA stabilization.
    J Gastroenterol. 2023 Jun 30. doi: 10.1007/s00535-023-02015.
    PubMed     Abstract available
    
    
    
40. YOSHIDA H, Shiokawa M, Kuwada T, Muramoto Y, et al
    Anti-integrin alphavbeta6 autoantibodies in patients with primary sclerosing cholangitis.
    J Gastroenterol. 2023 Jun 13. doi: 10.1007/s00535-023-02006.
    PubMed     Abstract available
    
    
    May 2023
41. KIM KA, Choi HY, Ki M, Jang ES, et al
    Epidemiological trends and outcomes of primary biliary cholangitis in South Korea between 2009 and 2019.
    J Gastroenterol. 2023 May 17. doi: 10.1007/s00535-023-01999.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Biliary Tract Diseases is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum